The role of carbohydrate antigen 125 in COVID-19

Dökümcü, Esra

doi:10.1016/j.mehy.2021.110590

Cited by 2 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HF condition is closely related to systemic inflammatory activity and congestion (hydrostatic pressure and serosal effusions). Congestion is a hemodynamic parameter and causes the disease to progress by integrating into the circle of the inflammatory process defined in HF ( 11 ). Activation of mesothelial cells in response to increased hydrostatic pressures, mechanical stress, and cytokine activation has been suggested to be the crucial mechanism being the synthesis of CA125 by mesothelial cells ( 12 ).…”

Section: Introductionmentioning

confidence: 99%

Early carbohydrate antigen 125 as a mortality predictor in hospitalized patients with coronavirus disease 2019

Moreno-Pérez

Núñez

Sandin-Rollan

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundCarbohydrate antigen 125 (CA125) is an indicator of inflammation, immune response, and impaired cardiac function. The aim was to investigate whether CA125 behaves as a biomarker of severity and poor clinical outcomes in hospitalized patients with coronavirus disease 2019 (COVID-19).MethodsSerum CA125 [Elecsys CA125 II assay-(Roche Diagnostics GmbH)] was measured in stored biobank samples from COVID-19 hospitalized patients between 01 March 2020 and 17 October 2021. Multiple logistic regression models were built to explore the association between CA125 and clinical outcomes [in-hospital all-cause mortality, need for invasive mechanical ventilation (IMV), or non-invasive respiratory support (non-IRS)], estimating odds ratios (ORs; 95% CI). The gradient of risk of CA125 was evaluated by fractional polynomials.ResultsA total of 691 patients were included, median age of 63 years (50–76), men (57.2%), with high comorbidity. At admission, 85.8% had pneumonia. Median CA125 was 10.33 U/ml (7.48–15.50). The in-hospital mortality rate was 7.2%. After adjusting for confounding factors, CA125 ≥ 15.5 U/ml (75th percentile) showed an increased risk of death [OR 2.85(1.21–6.71)], as age ≥ 65 years, diabetes, and immunosuppression. Furthermore, CA125 as a continuous variable was positive and significantly associated with the risk of death after multivariate adjustment. The mean hospital stay of the patients with CA125 ≥ 15.5 U/ml was longer than the rest of the study population.ConclusionCA125 in the first 72 h of hospital admission seems a useful biomarker of mortality in hospitalized patients with moderate–severe COVID-19. If our findings are confirmed, the wide availability of this biomarker would make easy its widespread implementation in clinical practice.

show abstract

Section: Introductionmentioning

confidence: 99%